全文获取类型
收费全文 | 228852篇 |
免费 | 4495篇 |
国内免费 | 111篇 |
专业分类
耳鼻咽喉 | 1651篇 |
儿科学 | 8873篇 |
妇产科学 | 4492篇 |
基础医学 | 23251篇 |
口腔科学 | 2073篇 |
临床医学 | 20756篇 |
内科学 | 39866篇 |
皮肤病学 | 1406篇 |
神经病学 | 21579篇 |
特种医学 | 9837篇 |
外科学 | 33217篇 |
综合类 | 2891篇 |
一般理论 | 109篇 |
预防医学 | 25527篇 |
眼科学 | 3476篇 |
药学 | 12976篇 |
中国医学 | 686篇 |
肿瘤学 | 20792篇 |
出版年
2023年 | 296篇 |
2022年 | 444篇 |
2021年 | 1030篇 |
2020年 | 705篇 |
2019年 | 1067篇 |
2018年 | 22955篇 |
2017年 | 18183篇 |
2016年 | 20428篇 |
2015年 | 2126篇 |
2014年 | 2478篇 |
2013年 | 3457篇 |
2012年 | 10798篇 |
2011年 | 25014篇 |
2010年 | 20950篇 |
2009年 | 13528篇 |
2008年 | 23087篇 |
2007年 | 25533篇 |
2006年 | 4398篇 |
2005年 | 6138篇 |
2004年 | 7147篇 |
2003年 | 7886篇 |
2002年 | 5762篇 |
2001年 | 744篇 |
2000年 | 751篇 |
1999年 | 640篇 |
1998年 | 883篇 |
1997年 | 807篇 |
1996年 | 566篇 |
1995年 | 580篇 |
1994年 | 520篇 |
1993年 | 395篇 |
1992年 | 282篇 |
1991年 | 299篇 |
1990年 | 315篇 |
1989年 | 280篇 |
1988年 | 241篇 |
1987年 | 221篇 |
1986年 | 195篇 |
1985年 | 201篇 |
1984年 | 212篇 |
1983年 | 189篇 |
1982年 | 240篇 |
1981年 | 210篇 |
1980年 | 194篇 |
1979年 | 98篇 |
1978年 | 125篇 |
1977年 | 59篇 |
1976年 | 69篇 |
1974年 | 87篇 |
1938年 | 60篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
41.
42.
Jonathan Halford Gandis Mazeika Susan Slifer Marcy Speer Ann M Saunders Warren J Strittmatter Joel C Morgenlander 《Movement disorders》2006,21(4):540-542
Ninety-seven inpatients with tardive dyskinesia (average AIMS score = 13), the majority of whom were schizophrenic, were studied. Forty patients were Caucasian, and 57 were African-American. The APOE genotypes of these patients were compared to previously published genotypes of controls and with previously published studies of APOE genotypes in patients with schizophrenia. There were no significant differences in APOE allele frequencies comparing the African-American tardive dyskinesia population and the African-American control groups. In contrast, significant (< 0.05) P values were obtained comparing the Caucasian tardive dyskinesia population to the Caucasian controls, when comparing allele frequencies and genotypic frequencies. This study suggests that Caucasians bearing an APOE2 allele are at increased risk of developing tardive dyskinesia, whereas African-Americans are not. APOE genotype-specific risks of both tardive dyskinesia and Alzheimer's disease that vary across populations could be due to recruitment of patients or controls or could be due to modifying effects of differing genetic or environmental backgrounds. The mechanism by which the APOE2 allele increases risk of tardive dyskinesia is not known. Further information about the mechanisms of increased risk of tardive dyskinesia could result in stratification of prescribing practices weighing the costs of medications against the relative risk of side effects. 相似文献
43.
44.
Marlene L Hauck Susan M LaRue William P Petros Jean M Poulson Daohai Yu Ivan Spasojevic Amy F Pruitt Allison Klein Beth Case Donald E Thrall David Needham Mark W Dewhirst 《Clinical cancer research》2006,12(13):4004-4010
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a low temperature sensitive liposome (LTSL) when given concurrently with local hyperthermia to canine solid tumors. EXPERIMENTAL DESIGN: Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia. LTSL-doxorubicin was given (0.7-1.0 mg/kg i.v.) over 30 minutes during local tumor hyperthermia in a standard phase I dose escalation study. Three treatments, given 3 weeks apart, were scheduled. Toxicity was monitored for an additional month. Pharmacokinetics were evaluated during the first treatment cycle. RESULTS: Twenty-one patients were enrolled: 18 with sarcomas and 3 with carcinomas. Grade 4 neutropenia and acute death secondary to liver failure, possibly drug related, were the dose-limiting toxicities. The maximum tolerated dose was 0.93 mg/kg. Other toxicities, with the possible exception of renal damage, were consistent with those observed following free doxorubicin administration. Of the 20 dogs that received > or = 2 doses of LTSL-doxorubicin, 12 had stable disease, and 6 had a partial response to treatment. Pharmacokinetic variables were more similar to those of free doxorubicin than the marketed liposomal product. Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue. CONCLUSION: LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors. It was well tolerated and resulted in favorable response profiles in these patients. Additional evaluation in human patients is warranted. 相似文献
45.
46.
47.
48.
49.
50.